How to Check Pramodini Medicare IPO Allotment Status

Pramodini Medicare Limited is a diagnostic healthcare services provider based in Vijayawada, Andhra Pradesh. The company was originally incorporated in September 2000 as Pramodini Medicare Private Limited and was subsequently converted into a public limited company in November 2025.  

The company provides diagnostic services through four principal operating models: Public-Private Partnerships with government hospitals and teaching hospitals, Private-Private Partnerships with private hospitals, strategic partnerships with Government of India PSUs, and standalone private diagnostic centres.  

Its diagnostic operations are focused on providing healthcare testing and related services through institutional partnerships and its own centres. The company is headquartered in Vijayawada and operates under the Pramodini Diagnostics brand. 

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Pramodini Medicare IPO is a book-built SME issue proposed for listing on the NSE Emerge platform. The company's IPO documents name Smart Horizon Capital Advisors Private Limited as the book-running lead manager and Purva Sharegistry (India) Private Limited as the registrar.  

The IPO opened for subscription on August 12, 2026 and closed on August 14, 2026. The issue price was ₹118 per share, according to contemporary IPO market data.  

Registrar:  Purva Sharegistry (India) Pvt.Ltd 

NSE: NSE IPO Allotment Status Page 

Pramodini Medicare IPO Subscription Status 

Pramodini Medicare IPO was subscribed 3.87 times on August 14, 2026, based on the final subscription data provided. The issue received full subscription across all three investor categories, with Non-Institutional Investors recording the highest demand.

The QIB category was subscribed 3.66 times on the final day. 

The NII category recorded the strongest demand, reaching 4.96 times subscription. 

Individual Investors subscribed 3.49 times, while the overall issue closed at 3.87 times. 

Demand accelerated notably on the final day. Overall subscription increased from 0.91 times on Day 2 to 3.87 times on Day 3, taking the IPO comfortably past full subscription. 

Pramodini Medicare IPO Share Price and Investment Details 

Pramodini Medicare IPO is an NSE Emerge SME issue, with contemporary IPO market data indicating an issue price of ₹118 per share.  

The issue attracted moderate but broad-based investor demand. While the IPO remained below full subscription at 0.91 times on Day 2, final-day bidding lifted overall demand to 3.87 times. 

The NII category led at 4.96 times, followed by QIBs at 3.66 times and Individual Investors at 3.49 times. Given the oversubscription across all categories, successful allocation will depend on the final basis of allotment. 

Listing performance will ultimately depend on broader SME-market conditions and investor demand when Pramodini Medicare shares begin trading. 

Utilisation of IPO Proceeds 

According to the company's IPO documents, the proceeds from the issue are intended to support the company's growth plans and other business requirements. The IPO is designed to provide additional capital as Pramodini Medicare expands its diagnostic healthcare operations.  

Investors should refer to the final prospectus for the precise allocation of proceeds and any changes from the objects initially disclosed in the DRHP. 

Business Overview 

Pramodini Medicare operates in India's diagnostic healthcare services industry, providing services through a combination of government partnerships, private hospital partnerships, PSU relationships and independently operated diagnostic centres.  

The company's revenue model therefore provides exposure to both institutional healthcare demand and private diagnostic spending. Its partnership-based approach can enable the company to expand its diagnostic presence without relying solely on standalone centres. 

Pramodini Medicare has also demonstrated growth in its financial performance. Total income increased from ₹30.96 crore in FY23 to ₹35.79 crore in FY24 and ₹38.55 crore in FY25. Profit after tax increased from ₹5.88 crore in FY23 to ₹7.62 crore in FY24 and ₹11.55 crore in FY25.  

EBITDA increased from ₹14.67 crore in FY23 to ₹15.54 crore in FY24 and ₹20.97 crore in FY25, indicating improving operating performance over the period.  

Key strengths include its experience in diagnostic healthcare, diversified operating models, relationships with government and private healthcare institutions, established presence in Vijayawada and improving profitability. 

Investors should also consider risks associated with geographical concentration, dependence on institutional partnerships, healthcare regulation, competition from larger diagnostic chains, availability of qualified medical professionals and the capital required to expand diagnostic infrastructure.